• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Gender inequity

Male and female mice react differently to UVB exposure, calling into question the true basis behind higher incidences of skin cancer in men. Is it really because men spend more time in the sun, or is that a fallacy?

Key Points

Columbus, Ohio - Differences in the biochemistry of male skin make it significantly more likely to develop tumors when exposed to ultraviolet (UV) B, studies in a murine model show.

The key differences are in the inflammatory and antioxidant responses.

"Historically, the thought has been that men get twice as much skin cancer because they have jobs requiring them to be out in the sun more, getting more damage. We really thought that our study was going to support that hypothesis. It ended up not," says Tatiana Oberyszyn, Ph.D., an assistant professor at the Ohio State University Medical Center.

"The first time we did the male mice, they were not pink at all, especially compared to the female mice. I asked Jennifer Thomas-Ahner, the graduate student working on the project, to check the lights to make sure they are working properly," Dr. Oberyszyn tells Dermatology Times.

"That was a bit of a surprise; we never anticipated that the male mice wouldn't respond as well as the females," she says.

Dr. Oberyszyn says a decade of work with the outbred Skh-1 mouse model has established "a clear link between acute inflammation and tumor development." If a compound decreased parameters of inflammation, "We could pretty much predict it would decrease tumor development. What this new research suggests is that with male mice, that may not be true."

At 48 hours, the females had a fivefold greater increase in skin fold thickness from baseline than males, a marker of edema. They also had three times the increase in myeloperoxidase activity, a measure of neutrophil infiltration. Both are key markers of an inflammatory response.

Dr. Oberyszyn and her assistant also found that antioxidant activity in both males and females declined after exposure to UVB, but females had significantly more antioxidant activity, both at baseline and after exposure to UVB. This suggests to Dr. Oberyszyn that males either are more susceptible to the formation of 8-oxo-dG adducts or have a less effective oxidative repair capacity.

The initial work led to a longer study that exposed male and female mice to the same dose of UVB three times a week.

Based on the tumor count model, male mice had ~50 percent more tumors than female mice at every time point from week 16 forward. Histology showed that the male's tumors were more likely to be malignant (38.5 percent vs. 18.2 percent) and were more likely to be fully invasive squamous cell carcinomas (14.6 percent vs. 2.9 percent).

Future research includes oral and topical application of antioxidants "to see if we can make male mouse skin look more like female mouse skin" and its response to UVB exposure.

The research suggests to Dr. Oberyszyn that men probably are not receiving the same inflammatory signals as women to get out of the sun, which "probably contributes to their staying out longer." It also suggests that an anti-inflammatory approach that may help prevent the development of skin tumors in women may not have the same efficacy in men.

"It is possible that with male skin you need a combination of antioxidants as well as anti-inflammatories," she says. While females also may benefit from antioxidants, the best ratios of the two agents may be gender-specific.

The focus of skincare, she says, should include encouraging both men and women to be smart and to use sunscreen.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.